Cell-based assay mechanistic

Secondary assays depend on the project. Where the primary screen was a cell-based assay, the secondary assay may be a radioligand competition binding assay. In other cases, such as where the primary screen was a biochemical assay, the secondary assay may be a cellular assay, and may be functional or mechanistic. One of the issues that may arise at this stage is that compounds with reasonable activity in the primary assay may not show activity in the secondary assay. There can be a number of reasons for this, including insufficient potency, inability of the compound to get into cells, or a higher intracellular concentration of the natural ligand (e.g., ATP) if the inhibitor is a competitive inhibitor. It is often necessary at this stage to prepare additional compounds in the series to get compounds of sufficient potency and/or permeability so that cellular activity can be demonstrated. 

Eight classes of natural products that are inhibitors of FPTase have been described from a variety of microbial sources. Mechanistically, these compounds are competitive with FPP. All compounds, with the exception of manumycins, possess negative charges in the form of one or more carboxylic, sulfuric or phosphoric acids, and are not active in cell-based assays. The lack of cell-based activities for these classes of natural products is linked to the negative charge present in these compounds that appears to be detrimental for cell wall penetration. Manumycin, in contrast, is not only active in cell-based assays but is also active in animal models. 

Forster 1998). Similar effects were seen with benzodiazepines (Drexler et al. 2010) and barbiturates (Lukatch and Maciver 1996) which are used clinically to induce sedation. To date, brain slice assays have not been utiUzed in the assessment of potential sedative effects, and this is unlikely to be used as a routine screen in preclinical safety assessment. However, in cases such as those discussed above, where in vitro correlates of in vivo effects are seen, brain slice studies could be used to gain mechanistic understanding of a sedative effect or to enable comparison of compounds from different chemical series or classes. Furthermore, if mechanistic studies revealed a potential mechanism of drug-induced sleep disruption (e.g., identified the involvement of a specific receptor), it would be possible to develop much higher-throughput cell-based assays to screen out this activity during chemical design. 

As with all drug-induced adverse events, there is a drive to develop predictive in vitro models to enable assessment of CNS ADRs in the early phases of drug discovery. However, due to the complex structure of the CNS, it has proved difficult to model in cell-based systems, and efforts in this area have been of limited success. For this reason, in vitro CNS assays are rarely used as fronthne screens in drug safety screening, and use has been mainly hmited to mechanistic studies, particularly using electrophysiological techniques. 

CELL-BASED IN VITRO ASSAYS FOR SCREENING AND MECHANISTIC INVESTIGATIONS TO GI TOXICITY... 

Advances in the understanding of the immunobiology of skin sensitization have led to the establishment of predictive in vivo tests which not only identify sensitizing hazards but also characterize their potency. Recently, appreciation of the underlying biology has also resulted in the development of mechanistically based in vitro alternatives which offer the prospect of the replacement of current in vivo methods. Assays under active validation include the Direct Peptide Reactivity Assay (DPRA), the human Cell Line Activation Test (h-CLAT), and KeratinoSens. None of the methods have a sufficient level of accuracy or freedom from applicability domain limitations to allow them to act as a standalone replacement. Consequently, it will be necessary to consider how to deploy these assays, perhaps in combination and/or in a structured assessment of skin sensitization hazard, to ensure at least the same level of predictive accuracy as the in vivo methods. However, a challenge remains the capacity of these methods to provide potency information on skin-sensitizing chemicals has yet to be assessed. This is an essential requirement for future risk assessment without use of animal models if we are to retain the same level of human health protection that is currently delivered. 

Another strategy for exposure assessment analysis is based on the measurable binding of pesticides or metabolites to specific ceU receptors. In the areas of hazard assessment and exposure assessment, in vitro studies to assess mechanistic processes of toxicity, have been developed. These studies utilise new and innovative technologies such as genomics, transcriptomics and proteomics which allows the identification of in vitro clusters of genes and proteins that can be induced or silenced by pesticides or metabolites. The key point in these cases is to vahdate in vitro studies with in vivo exposure assessment by testing if mechanistic responses found in vitro correlates with in vivo exposure doses. This type of integrated, mechanism-driven in vitro to in vivo approach relies extensively on the use of cell assays to develop new biomarkers. 

In vitro tests based on cell culture techniques, though with various restrictions as models for the behavior of cells in an organism, are very functional in the screening of NPs and in mechanistic assays they are comparatively economical and can have a highthroughput... 

---